News
Corporate events and presentations
GRIN Therapeutics Presents Multiple Clinical Development Updates for Radiprodil at 2025
ILAE International Epilepsy Congress
September 2, 2025 – GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies to treat serious neurodevelopmental disorders, today announced presentations of three abstracts during the International League Against Epilepsy’s (ILAE) 36th International Epilepsy Congress in Lisbon, Portugal.
Neurvati Neurosciences and GRIN Therapeutics Announce Appointment of Gail Farfel, PhD to Their Boards of Directors
June 18, 2025 – Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of therapies to people affected by neurological and psychiatric disorders, and GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced the appointment of Gail M. Farfel, PhD to the board of directors of both companies.
GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America
May 27, 2025 – GRIN Therapeutics, Inc. and Angelini Pharma, part of the privately owned Angelini Industries, today announced a collaboration for the development and commercial rights outside of North America of GRIN Therapeutics’ investigational drug radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders.
Press releases
Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
November 13, 2025 – Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, today announced the appointment of Carlos Martin as Chief Commercial Officer (CCO).
GRIN Therapeutics Presents Multiple Clinical Development Updates for Radiprodil at 2025
ILAE International Epilepsy Congress
September 2, 2025 – GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies to treat serious neurodevelopmental disorders, today announced presentations of three abstracts during the International League Against Epilepsy’s (ILAE) 36th International Epilepsy Congress in Lisbon, Portugal.
Neurvati Neurosciences and GRIN Therapeutics Announce Appointment of Gail Farfel, PhD to Their Boards of Directors
June 18, 2025 – Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of therapies to people affected by neurological and psychiatric disorders, and GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced the appointment of Gail M. Farfel, PhD to the board of directors of both companies.
GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America
May 27, 2025 – GRIN Therapeutics, Inc. and Angelini Pharma, part of the privately owned Angelini Industries, today announced a collaboration for the development and commercial rights outside of North America of GRIN Therapeutics’ investigational drug radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders.
GRIN Therapeutics Receives Positive Opinion for EU Orphan Designation for Radiprodil for Treatment of GRIN-Related Neurodevelopmental Disorder
May 6, 2025 – GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive orphan designation for radiprodil, an investigational drug for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD).
GRIN Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
April 1, 2025 – GRIN Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric modulator.
GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of
GRIN-Related Neurodevelopmental Disorder
March 17, 2025 – GRIN Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for its investigational drug, radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD).
GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil
February 25, 2025 – GRIN Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to radiprodil, the company’s investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B).
GRIN Therapeutics Presents Data from Honeycomb Trial of Radiprodil at the American Epilepsy Society Annual Meeting
December 9, 2024 – Previously reported Honeycomb topline results showed radiprodil was generally well-tolerated and a key secondary analysis demonstrated a median reduction of 86% in countable motor seizure frequency consistent across GRIN genotypes with gain-of-function variants.
GRIN Therapeutics to Present Data from Honeycomb Trial of Investigational Radiprodil in GRIN-Related Neurodevelopmental Disorder
November 21, 2024 – Presentation at the American Epilepsy Society Annual Meeting will also highlight proposed design of planned Phase 3 study of radiprodil in children with gain-of-function variants.
GRIN Therapeutics Announces Initiation of Astroscape Clinical Trial of Radiprodil
for Treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II
October 8, 2024 – Dosing of patients in the second clinical research program for radiprodil follows recent announcement of positive topline data from the Honeycomb trial in GRIN-related neurodevelopmental disorder.
GRIN Therapeutics Announces Positive Topline Data from Honeycomb Trial of Radiprodil in GRIN-Related Neurodevelopmental Disorder
September 9, 2024 – Radiprodil appeared to be generally well-tolerated in patients with gain-of-function (GoF) variants in GRIN genes, both with and without countable motor seizures (CMS) at baseline.
GRIN Therapeutics to Present New Data from Honeycomb Study
at ILAE Europe Epilepsy Congress
August 20, 2024 – Presentation to highlight topline data from ongoing Phase 1b study of investigational radiprodil in children with GRIN-related neurodevelopmental disorder.
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and
Chair of Company Board of Directors
April 15, 2024 – Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of proven-effective therapies to people affected by neurological and psychiatric disorders, today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company’s board of directors.
GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders
March 23, 2023 – Milestone represents initiation of first-ever clinical trial using NR2B-negative allosteric modulator to treat GRIN-related disorders.
Media Contact
Elliot Ruiz
elliot.ruiz@neurvati.com